In addition, epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusion genes have been identified in lung adenocarcinoma, and are considered as biomarkers for EGFR and ALK inhibitors [3–7]. The gene discussed is ALK; the disease is lung adenocarcinoma.